Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling.
TLR4 is the signal-transducing receptor for structurally diverse microbial molecules such as bacterial LPS, respiratory syncytial virus fusion (F) protein, and chlamydial heat shock protein 60. Previous studies associated two polymorphic mutations in the extracellular domain of TLR4 (Asp(299)Gly and Thr(399)Ile) with decreased LPS responsiveness. To analyze the molecular basis for diminished responsiveness, site-specific mutations (singly or coexpressed) were introduced into untagged and epitope (Flag)-tagged wild-type (WT) TLR4 expression vectors to permit a direct comparison of WT and mutant signal transduction. Coexpression of WT TLR4, CD14, and MD-2 expression vectors in HEK293T cells was first optimized to achieve optimal LPS-induced NF-kappaB reporter gene expression. Surprisingly, transfection of cells with MD-2 at high input levels often used in the literature suppressed LPS-induced signaling, whereas supraoptimal CD14 levels did not. Under conditions where WT and polymorphic variants were comparably expressed, significant differences in NF-kappaB activation were observed in response to LPS and two structurally unrelated TLR4 agonists, chlamydial heat shock protein 60 and RSV F protein, with the double, cosegregating mutant TLR4 exhibiting the greatest deficiency. Overexpression of Flag-tagged WT and mutant vectors at input levels resulting in agonist-independent signaling led to equivalent NF-kappaB signaling, suggesting that these mutations in TLR4 affect appropriate interaction with agonist or coreceptor. These data provide new insights into the importance of stoichiometry among the components of the TLR4/MD-2/CD14 complex. A structural model that accounts for the diminished responsiveness of mutant TLR4 polymorphisms to structurally unrelated TLR4 agonists is proposed.
Rallabhandi
Prasad
P
Department of Microbiology and Immunology, University of Maryland, 660 West Redwood Street, Baltimore, MD 21201, USA.
Bell
Jessica
J
Boukhvalova
Marina S
MS
Medvedev
Andrei
A
Lorenz
Eva
E
Arditi
Moshe
M
Hemming
Val G
VG
Blanco
Jorge C G
JC
Segal
David M
DM
Vogel
Stefanie N
SN
D019943:Amino Acid Substitution / Q000235:genetics; D001224:Aspartic Acid / Q000235:genetics; D002460:Cell Line; D005110:Extracellular Space / Q000235:genetics / Q000276:immunology; D014644:Genetic Variation; D005998:Glycine / Q000235:genetics; D006801:Humans; D007532:Isoleucine / Q000235:genetics; D018950:Lipopolysaccharide Receptors / Q000737:chemistry* / Q000235:genetics* / Q000502:physiology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051218:Lymphocyte Antigen 96 / Q000737:chemistry* / Q000235:genetics* / Q000502:physiology; D009842:Oligopeptides; D010455:Peptides / Q000235:genetics; D011110:Polymorphism, Genetic; D011485:Protein Binding / Q000235:genetics / Q000276:immunology; D017434:Protein Structure, Tertiary / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology*; D013912:Threonine / Q000235:genetics; D051197:Toll-Like Receptor 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics*; D014162:Transfection
C495377:LY96 protein, human; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D051218:Lymphocyte Antigen 96; D009842:Oligopeptides; D010455:Peptides; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D007532:Isoleucine; D013912:Threonine; D001224:Aspartic Acid; C085706:FLAG peptide; D005998:Glycine